Phase 1 N=25 AB103 Peptide Antagonist in Healthy Volunteers
Healthy Volunteer Safety Study
Primary: Number Adverse Events (AEs) — 7; 2; 1; 9 adverse events
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=48 Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects
Type 2 Diabetes Mellitus
Primary: Cmax (Maximum Observed Plasma Concentration) — 161.675; 193.366; 97.811; 117.001 ng/mL
Phase 1 N=82 MEK and MET Inhibition in Colorectal Cancer
Solid Tumor · Colorectal Cancer
Primary: Maximal Tolerated Dose (MTD) of PD-0325901 and PF-02341066 /PF-02341066 or Binimetinib With PF-02341066 — 0; 0; 0; 1 Dose Limiting Toxicities (DLTs)
Phase 1 N=59 RADVAX: A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers
Metastatic Cancers
Primary: Number of Adverse Events — 428 Adverse Events
Phase 1 N=20 Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC
Metastatic Colorectal Cancer · MSS
Primary: Feasibility Rate of a Combined Therapy — 18 Participants
Phase 1 N=25 Study to Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated Human Immunodeficiency Virus (HIV-1) Infected Controllers
HIV-1 Infection
Primary: Percentage of Participants Experiencing Treatment Emergent Serious Adverse Events (TESAEs) and Treatment Emergent Adverse Events (TEAEs) — 0; 0; 0; 33.3 percentage of…
Phase 1 N=46 Effect of Food on the Pharmacokinetics of Apremilast (CC-10004) in Healthy Adults
Healthy Volunteer
Primary: Maximum Observed Plasma Concentration (Cmax) of Apremilast — 339.86; 333.85 ng/mL
Phase 1 N=55 A Safety, Tolerability and Pharmacokinetic Study of CPP-115
Cocaine Dependency
Primary: Safety of Single Oral Doses — 0; 0; 0; 0 participants
Phase 1 N=26 A Study of LY3202626 in Healthy Participants
Healthy
Primary: Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3202626 — 27.9; 36.1; 39.4 nanogram/milliliter (ng/mL)
Phase 1 N=33 Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)
Metastatic Breast Cancer
Primary: Treatment-Emergent Adverse Events (TEAEs) — 106; 99; 506 adverse events
Phase 1 N=6 A Study of [¹⁴C]-LY3202626 in Healthy Male Participants
Healthy
Primary: Fecal Excretion of Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered — 31.3 percentage of the total radioactive dose
Phase 1 N=32 Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients
Diffuse Large B Cell Lymphoma · Primary Mediastinal Lymphoma · Mantle Cell Lymphoma
Primary: Part A: Effect of CYP3A Inhibition by Fluconazole on the PK of Tazemetostat (AUC0-t, AUC0-8) — 1340; 4100 h*ng/mL
Phase 1 N=94 A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease
Healthy Volunteers · Alzheimer Disease
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 Participants
Phase 1 N=36 Effects of Age and Sex on the Pharmacokinetics of Apremilast in Healthy Adults
Healthy Volunteer
Primary: Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) of Apremilast — 2832; 3235 h*ng/mL
Phase 1 N=24 Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects
Hepatic Impairment · Healthy Volunteers
Primary: Maximum Observed Plasma Concentration (Cmax) — 532.2; 835.5; 668.3; 658.6 nanogram per milliliter (ng/mL)